These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 12947010)

  • 41. Comparison of potential markers of farnesyltransferase inhibition.
    Adjei AA; Davis JN; Erlichman C; Svingen PA; Kaufmann SH
    Clin Cancer Res; 2000 Jun; 6(6):2318-25. PubMed ID: 10873082
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro.
    Ochiai N; Uchida R; Fuchida S; Okano A; Okamoto M; Ashihara E; Inaba T; Fujita N; Matsubara H; Shimazaki C
    Blood; 2003 Nov; 102(9):3349-53. PubMed ID: 12842991
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Protein farnesyltransferase inhibitors.
    Ayral-Kaloustian S; Salaski EJ
    Curr Med Chem; 2002 May; 9(10):1003-32. PubMed ID: 12733981
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.
    Lara PN; Law LY; Wright JJ; Frankel P; Twardowski P; Lenz HJ; Lau DH; Kawaguchi T; Gumerlock PH; Doroshow JH; Gandara DR
    Anticancer Drugs; 2005 Mar; 16(3):317-21. PubMed ID: 15711184
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
    Sun J; Ohkanda J; Coppola D; Yin H; Kothare M; Busciglio B; Hamilton AD; Sebti SM
    Cancer Res; 2003 Dec; 63(24):8922-9. PubMed ID: 14695209
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies.
    Cortes JE; Kurzrock R; Kantarjian HM
    Semin Hematol; 2002 Jul; 39(3 Suppl 2):26-30. PubMed ID: 12214290
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias.
    Lancet JE; Rosenblatt JD; Karp JE
    Semin Hematol; 2002 Jul; 39(3 Suppl 2):31-5. PubMed ID: 12214291
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
    Patnaik A; Eckhardt SG; Izbicka E; Tolcher AA; Hammond LA; Takimoto CH; Schwartz G; McCreery H; Goetz A; Mori M; Terada K; Gentner L; Rybak ME; Richards H; Zhang S; Rowinsky EK
    Clin Cancer Res; 2003 Oct; 9(13):4761-71. PubMed ID: 14581347
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia.
    Mesa RA; Tefferi A; Gray LA; Reeder T; Schroeder G; Kaufmann SH
    Leukemia; 2003 May; 17(5):849-55. PubMed ID: 12750696
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Farnesyltransferase inhibitors and their role in the treatment of multiple myeloma.
    Santucci R; Mackley PA; Sebti S; Alsina M
    Cancer Control; 2003; 10(5):384-7. PubMed ID: 14581893
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.
    Gore L; Holden SN; Cohen RB; Morrow M; Pierson AS; O'Bryant CL; Persky M; Gustafson D; Mikule C; Zhang S; Palmer PA; Eckhardt SG
    Ann Oncol; 2006 Nov; 17(11):1709-17. PubMed ID: 16980604
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate.
    Caraglia M; D'Alessandro AM; Marra M; Giuberti G; Vitale G; Viscomi C; Colao A; Prete SD; Tagliaferri P; Tassone P; Budillon A; Venuta S; Abbruzzese A
    Oncogene; 2004 Sep; 23(41):6900-13. PubMed ID: 15286715
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].
    Thomas X; Elhamri M
    Bull Cancer; 2005 Mar; 92(3):227-38. PubMed ID: 15820917
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
    Cortes J
    Clin Lymphoma; 2003 Aug; 4 Suppl 1():S30-5. PubMed ID: 14556673
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors.
    Moulder SL; Mahany JJ; Lush R; Rocha-Lima C; Langevin M; Ferrante KJ; Bartkowski LM; Kajiji SM; Noe DA; Paillet S; Sullivan DM
    Clin Cancer Res; 2004 Nov; 10(21):7127-35. PubMed ID: 15534083
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.
    deSolms SJ; Ciccarone TM; MacTough SC; Shaw AW; Buser CA; Ellis-Hutchings M; Fernandes C; Hamilton KA; Huber HE; Kohl NE; Lobell RB; Robinson RG; Tsou NN; Walsh ES; Graham SL; Beese LS; Taylor JS
    J Med Chem; 2003 Jul; 46(14):2973-84. PubMed ID: 12825937
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft.
    Delmas C; End D; Rochaix P; Favre G; Toulas C; Cohen-Jonathan E
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6062-8. PubMed ID: 14676133
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.
    Delmas C; Heliez C; Cohen-Jonathan E; End D; Bonnet J; Favre G; Toulas C
    Int J Cancer; 2002 Jul; 100(1):43-8. PubMed ID: 12115585
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
    Buzzeo R; Enkemann S; Nimmanapalli R; Alsina M; Lichtenheld MG; Dalton WS; Beaupre DM
    Clin Cancer Res; 2005 Aug; 11(16):6057-64. PubMed ID: 16115951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.